Sign In
Buy STOK
$30.97
-0.0300 (-0.0968%)
At Close: Jun 22, 2026
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Tuesday, 16'th Jun 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
01:18pm, Monday, 08'th Jun 2026
Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
4 Biotech Stocks Investors Should Watch in 2026
11:55am, Friday, 05'th Jun 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
10:56am, Thursday, 04'th Jun 2026
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement a
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
04:01pm, Thursday, 28'th May 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
12:27pm, Thursday, 21'st May 2026
STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA filing plans.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Monday, 18'th May 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics Q1 Earnings Call Highlights
12:09am, Saturday, 09'th May 2026
Stoke Therapeutics NASDAQ: STOK said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
02:21am, Friday, 08'th May 2026
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
08:12pm, Thursday, 07'th May 2026
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to earnings of $1.9 per share a year ago.
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
04:01pm, Thursday, 07'th May 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome
04:39pm, Friday, 01'st May 2026
I initiate Stoke Therapeutics with a Buy rating, driven by late-stage progress for zorevunersen in SCN1A Dravet Syndrome. STOK's phase 3 EMPEROR trial for zorevunersen targets mid-2027 data and a roll
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:01pm, Thursday, 16'th Apr 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
04:01pm, Wednesday, 08'th Apr 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
04:01pm, Tuesday, 07'th Apr 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h
